Prolonged-release fampridine: a guide to its use in multiple sclerosis in the EU

被引：0
作者：
Katherine A. Lyseng-Williamson
机构：
[1] Adis,
来源：
Drugs & Therapy Perspectives | 2012年 / 28卷 / 12期
关键词：
Multiple Sclerosis; Placebo Recipient; Expand Disability Status Scale; Primary Efficacy Variable; Potassium Channel Blocker;
D O I：
10.1007/BF03262139
中图分类号：
学科分类号：
摘要：
Prolonged-release (PR) fampridine (Fampyra®), a potassium channel blocker, is the first agent to be specifically indicated for the improvement of walking in patients with multiple sclerosis (MS). In clinical trials in patients with MS with impaired walking, PR fampridine 10 mg twice daily improved walking ability to a significantly greater extent than placebo, with improvements being maintained with long-term therapy. PR fampridine 10 mg twice daily is generally well tolerated.
引用
收藏
页码：1 / 4
页数：3
相关论文
共 22 条
[1]  
Panitch H.(2011)Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability Expert Opin Pharmacother 12 1511-21
[2]  
Applebee A.(2010)Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis Mult Scler 16 406-11
[3]  
Tallantyre E.C.(2011)Impact of walking impairment in multiple sclerosis: perspectives of patients and care partners Patient 4 189-201
[4]  
Bo L.(2006)Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment Pharmacol Ther 111 224-59
[5]  
Al-Rawashdeh O.(2012)Clinical overview of the seizure risk of dalfampridine Expert Opin Drug Saf 11 651-7
[6]  
LaRocca N.(2010)Dalfampridine extended release in multiple sclerosis CNS Drugs 24 883-91
[7]  
Judge S.I.V.(2010)A phase 3 trial of extended release oral dalfampridine in multiple sclerosis Ann Neurol 68 494-502
[8]  
Bever C.T.(2009)Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial Lancet 373 732-8
[9]  
Haut S.R.(2012)The safety profile of dalfampridine extended release in multiple sclerosis clinical trials Clin Ther 34 1056-69
[10]  
Bienen E.J.(undefined)undefined undefined undefined undefined-undefined
123